Tennessee Senate Bill SB2149

Tennessee 2025-2026 Regular Session

• Introduced: 2/2/26
• Engrossed: 4/15/26
• Enrolled: 5/5/26
• Passed: 5/22/26
• Chaptered: 5/27/26

Caption

AN ACT to amend Tennessee Code Annotated, Title 9; Title 33; Title 53; Title 63 and Title 68, relative to clinical trials.

Impact

If enacted, the bill will create a special fund known as the Tennessee mental health innovation fund to support these clinical trials. It mandates the collaboration between drug developers, research institutions, and hospitals to create a cohort that will apply for FDA approval and engage in clinical research. The establishment of this program is positioned as a necessary response to the growing opioid crisis and aims to enhance the state's capacity to lead innovative mental health treatment solutions.

Summary

Senate Bill 2149, known as the 'Helping Open Pathways to Effective (HOPE) Treatment Act', aims to amend the Tennessee Code to facilitate clinical trials involving ibogaine—a psychoactive compound showing potential in treating various mental health and neurological conditions, including opioid use disorder and PTSD. The bill recognizes the difficulties in accessing regulated treatments due to ibogaine's Schedule I status and seeks to establish a framework for conducting clinical trials within the state while aligning with federal regulations.

Contention

While the bill presents potential benefits for patients seeking alternative treatments, it carries certain points of contention, especially concerning the regulatory implications of using ibogaine, which is still considered experimental. Concerns arise regarding the safety protocols for administering ibogaine in a clinical setting and the ethical implications of conducting trials on a substance that lacks extensive prior study under federal law. These factors could affect public perception and legislative support as the medical community grapples with integrating such therapies within existing healthcare frameworks.